Compare Canopy Growth Corp (CGC) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs US Bancorp — how do they compare? Canopy Growth Corp trades at $1 (market cap $399.40M), while US Bancorp trades at $64.51 (market cap $100.01B). The key difference: US Bancorp is far larger — about 250.4× Canopy Growth Corp's market cap, and US Bancorp pays a 3.24% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | USB | |
|---|---|---|
Market Cap | $399.40M | $100.01B |
Sector | Health | Financials |
52-Week High | $1.92 | $64.47 |
52-Week Low | $0.86 | $45.28 |
Enterprise Value | $356.90M | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CGC trades at $0.9701, up 4.07% in 24 hours, with a neutral technical signal and mixed analyst ratings (9 buy, 11 hold, 7 sell). The company reported Q1 2027 revenue growth of 13% year-over-year but continues to post net losses, with a negative net income margin of -92.38% in 2026. Cash flow trends show improving operational efficiency, though negative operating cash flow persists. Recent news highlights progress on profitability measures and anticipation of U.S. cannabis rescheduling decisions.
The outlook remains cautious due to persistent unprofitability and regulatory uncertainties, but cost-cutting and revenue growth offer potential upside. Key risks include high debt, competitive pressures, and delayed federal cannabis reforms. Analysts are divided, reflecting the stock's high-risk, high-reward profile amid ongoing turnaround efforts.
U.S. Bancorp (USB) trades at $63.94, up 0.2% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $70.27. The stock shows strong fundamentals with a P/E of 12.76, net income margin of 27.61%, and three consecutive quarterly EPS beats. Recent news highlights institutional buying and upbeat Q2 2026 results, though RSI levels suggest potential overbought conditions near-term.
Outlook is positive with earnings growth and dividend stability, but risks include interest rate sensitivity and competitive pressures. Upside potential exists if the company maintains its profit trajectory, supported by analyst buy ratings. Investors should monitor debt levels and economic shifts that could impact banking sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
